within Pharmacolibrary.Drugs.N_NervousSystem.N05A_Antipsychotics.N05AA04_Acepromazine;

model Acepromazine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.7222222222222223e-05,
    adminDuration = 600,
    adminMass = 0.1 / 1000000,
    adminCount = 1,
    Vd = 0.0066,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0053,
    k12 = 5.25e-05,
    k21 = 5.25e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Acepromazine</td></tr><tr><td>ATC code:</td><td>N05AA04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>0.1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.4</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Acepromazine is a phenothiazine derivative used primarily as a veterinary tranquilizer and sedative. It is commonly administered to dogs, cats, and horses for pre-anesthetic sedation, prevention of motion sickness, or for general tranquilization. Its use in humans is extremely rare today and primarily limited to veterinary medicine.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for acepromazine reported in healthy adult dogs after intravenous and intramuscular administration.</p><h4>References</h4><ol><li><p>Knych, HK, et al., &amp; Kass, PH (2018). Pharmacokinetics, pharmacodynamics, and metabolism of acepromazine following intravenous, oral, and sublingual administration to exercised Thoroughbred horses. <i>Journal of veterinary pharmacology and therapeutics</i> 41(4) 522–535. DOI:<a href=\"https://doi.org/10.1111/jvp.12494\">10.1111/jvp.12494</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29457257/\">https://pubmed.ncbi.nlm.nih.gov/29457257</a></p></li><li><p>Monteiro, ER, et al., &amp; Monteiro, BS (2016). Effects of acepromazine-morphine and acepromazine-methadone premedication on the minimum alveolar concentration of isoflurane in dogs. <i>Veterinary anaesthesia and analgesia</i> 43(1) 27–34. DOI:<a href=\"https://doi.org/10.1111/vaa.12265\">10.1111/vaa.12265</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25880906/\">https://pubmed.ncbi.nlm.nih.gov/25880906</a></p></li><li><p>Keating, S, et al., &amp; Edginton, A (2016). Effects of acepromazine or dexmedetomidine on fentanyl disposition in dogs during recovery from isoflurane anesthesia. <i>Veterinary anaesthesia and analgesia</i> 43(1) 35–43. DOI:<a href=\"https://doi.org/10.1111/vaa.12271\">10.1111/vaa.12271</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25943714/\">https://pubmed.ncbi.nlm.nih.gov/25943714</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N05AA04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Acepromazine;
